Overview

Staccato Loxapine Pulmonary Safety in Patients With COPD

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pulmonary safety of 2 doses of Staccato Loxapine within a day in patients with COPD.
Phase:
Phase 1
Details
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Treatments:
Loxapine